According to the industry analysis report titled ‘Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)’ available with MarketStudyReport, global idiopathic pulmonary fibrosis market, which amassed a valuation of USD 3271.3 million in 2020, is anticipated to garner sizable returns during 2021-2026.

Mounting usage of high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev), increasing prevalence of fibrotic disease, growing geriatric population, changing lifestyle patterns, and rising health awareness are some of the major factors driving the growth of the worldwide idiopathic pulmonary fibrosis market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4489502/  

Apart from this, technological advancements and increasing R&D efforts are also stimulating the overall industry outlook. Growing consumption of cigarettes has resulted in high prevalence of IPF across the globe. This in consort with rapid expansion of the healthcare sector are also complementing the business dynamics.

Notably, the most used non-pharmacological treatments include mechanical ventilation, oxygen therapy, lung transplantations, and pulmonary rehabilitation. However, the treatment approach in IPF is dependent on the stage of the disease, the patient's symptoms, and his overall health.

The global idiopathic pulmonary fibrosis market is fragmented into drug type, end-user, and regional contribution. Based on drug type the market is bifurcated on the basis of nintedanib, pirfenidone, and other segments. 

Moving on to the end-user spectrum, the market is segmented into academy & research organizations, hospitals & clinics, and others.

The geographical analysis of this business space extends to the Asia-Pacific, North America, and Europe, with major emphasis on countries such as China, India, Japan, Spain, France, the U.K., Germany, U.S., Italy, and Canada with North America leading the regional market share.

The leading companies operating in the global idiopathic pulmonary fibrosis market include AbbVie Inc., F. Hoffman-La Roche Ltd., Merck KGaA, Liminal BioSciences Inc., Galapagos NV, Medicinova Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Inc., Cipla Limited, and FibroGen, Inc.